RT Journal Article
SR Electronic
T1 BIUX2X2
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1039
OP 1039
VO 62
IS supplement 1
A1 BUI CONG
YR 2021
UL http://jnm.snmjournals.org/content/62/supplement_1/1039.abstract
AB 1039Objectives: To evaluate the prognostic significance of FDG PET/CT at different PD-L1 status level expression in patients with Adenocarcinoma lung cancer. Subjects and research methods: 114 patients with stage IIIb, IV of adenocarcinoma lung cancer were scanned with FDG PET / CT and tested for PD L1 before treatment from November 2018 to July 2020. Results: Average age 62.3 ± 8.4, sex (male/female: 63,2%/36,8%), stage IIIb (42.98%) and stage IV (57.0%). The rate of EGFR gene mutation and the rate without mutation were 55.3% and 44.7%, respectively. There were 43.0% of study patients do not reveal PD L1, 57.0% of study patients had positive results of PD L1. There was a statistically significant difference between the negative PD L1 group and positive PD L1 group by sex characteristics (p = 0.006), primary tumor trait (p = 0.03), stage of disease (p = 0.02), EGFR gene mutation (p = 0.03). The value of SUVmax at primary tumor in the positive PD L1 group was statistically significantly higher than the negative group (p = 0.04). The area under the curve (AUC) of the SUVmax in the prediction of positive PD L1 was calculated as 0.614 (p <0.05), while a combination of 4 factors, SUV max, sex, smoking status, and EGFR gene mutation were better independent prognostic indicator with AUC = 0.676. Conclusion: The FDG PET/CT results was valuable in predicting PD L1 status expression in patients with adenocarcinoma lung cancer.